➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Express Scripts
McKinsey
Baxter
Moodys

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACYCLOVIR SODIUM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for acyclovir sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00774280 Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen Completed Cooperative Study Group A for Hematology Phase 3 2002-05-01 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8.
NCT00855309 Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia Completed National Cancer Institute (NCI) Phase 3 2008-11-01 RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.
NCT00855309 Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia Completed Comprehensive Cancer Center of Wake Forest University Phase 3 2008-11-01 RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for acyclovir sodium

Condition Name

Condition Name for acyclovir sodium
Intervention Trials
Herpes Zoster 1
Herpes Simplex 1
Myelodysplastic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for acyclovir sodium
Intervention Trials
Mucositis 1
Neutropenia 1
Neoplasm Metastasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for acyclovir sodium

Trials by Country

Trials by Country for acyclovir sodium
Location Trials
United States 2
China 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for acyclovir sodium
Location Trials
Texas 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for acyclovir sodium

Clinical Trial Phase

Clinical Trial Phase for acyclovir sodium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for acyclovir sodium
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for acyclovir sodium

Sponsor Name

Sponsor Name for acyclovir sodium
Sponsor Trials
Cttq 1
Peking University People's Hospital 1
The University of Texas Health Science Center at San Antonio 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for acyclovir sodium
Sponsor Trials
Other 5
NIH 1
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Baxter
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.